Read + Share
. Correction to: A Multicenter, Phase 2, Randomized, Placebo-Controlled,
Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor
Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial
Infarction. Circulation 2022;146:e330.
PMID: 36469599
|
 |
|
